US Generic Injectables Market Research and Upcoming Forecast Report
© 2019 IMARC All Rights Reserved
Author: Elena Anderson, Marketing Manager | Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group
About IMARC Group
Report Description
International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and region.The s to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Description and Highlights Report Description US Generic Injectables Market Outlook 2026:
According to the latest report by IMARC Group, titled “US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the US generic injectables market reached a value of US$ 13.7 Billion in 2020. Generic injectables are used as an alternative to innovator injectables without compromising the effectiveness of the treatment. They are available in the market only after the expiry of the innovator injectables. Generic injectables are extensively used for treating numerous life-threatening and chronic diseases such as cardiovascular diseases, respiratory diseases, diabetes, rheumatoid arthritis, cancer, osteoporosis and osteoarthritis. They are less expensive than their branded counterparts, thereby contributing in substantial savings for the patients and healthcare providers. Request for a PDF sample of this report: https:// www.imarcgroup.com/us-generic-injectables-market/requestsample
Report Description and Highlights Report Description Highlights of the US generic injectables market:
Expiry of branded injectables is expected to drive the growth of the market in the coming years.The majority of generic injectables are distributed through hospitals.On the basis of therapeutic area, oncology generic injectables account for the majority of the market share. The US generic injectables market is being driven by numerous favourable factors. Due to sedentary lifestyles, poor eating habits and ageing population, an increasing number of people are suffering from various chronic diseases. As the treatment of these diseases depends on the use of generic injectables for improved effectiveness and cost savings, this has facilitated the growth of the market. Moreover, several branded injectables worth billions of dollars are projected to lose their patent protection in the coming years. This is expected to provide ample opportunities to the generic manufacturers so as to expand their business. Further, the low cost of generic injectables makes them an affordable healthcare option, owing to which the US government is supporting the production of these drugs. Besides this, the low competition in the market results in increased profit margins for the manufacturers. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.8% during 2021-2026.
Report Description and Highlights
Report Description Key Market Segmentation: Breakup by Therapeutic Area: •Oncology •Anesthesia •Anti-Infectives •Parenteral Nutrition •Cardiovascular
Breakup by Containers: •Vials •Ampoules •Premix •Prefilled Syringes
Breakup by Distribution Channel: •Hospitals •Retail Pharmacy
Report Description and Highlights
Report Description Competitive Landscape: •Hospira (Pfizer) •Hikma •APP (Fresenius Kabi) •Sagent •Sandoz (Novartis) •Henry Shein
Note: We are updating our research report 2021-2026. If you want to need latest primary and secondary data with Cost Module, Business Strategy, Distribution Channel, etc View Report TOC, Figures and Tables: https://www.imarcgroup.com/us-generic-injectables-market
A partial List of
We are the trusted business partners to the
Clients world's leading corporates, governments, and ourPartial ClientsList of institutions
Report Description and Highlights
Report Description
© 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
A partial List of
We are the trusted business partners to the
of Clients leading corporates, governments, and ourPartial ClientsListworld's institutions
Contact Us
FOR MORE DETAILS Visit us at :
https://www.imarcgroup.com Stay With Us:
TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com